Valneva to Present and Hold Investor Meetings at Upcoming U.S. and European Healthcare Conferences

Core Insights - Valneva SE, a specialty vaccine company, is engaging with institutional investors through presentations and 1-on-1 meetings at upcoming conferences in the U.S. and Europe [1][4] Group 1: Upcoming Events - Valneva will host moderated "fireside chat" presentations to discuss key value drivers and upcoming catalysts, particularly the Phase 3 trial outcomes for VLA15, its Lyme disease vaccine candidate partnered with Pfizer [2] - If the Phase 3 trial is successful, Pfizer plans to submit applications for U.S. and European market authorization in 2026, with a potential vaccine launch in the second half of 2027 [2] - The company will participate in several conferences, including the Guggenheim 2nd Annual Healthcare Innovation Conference on November 10, Stifel 2025 Healthcare Conference on November 11, and Jefferies London Healthcare Conference on November 19 [3] Group 2: Company Overview - Valneva specializes in developing, manufacturing, and commercializing prophylactic vaccines for infectious diseases, focusing on unmet medical needs [5] - The company has advanced multiple vaccines from early R&D to approvals and currently markets three proprietary travel vaccines [6] - Valneva's commercial business revenues support the advancement of its vaccine pipeline, which includes the only Lyme disease vaccine candidate in advanced clinical development and the world's most clinically advanced Shigella vaccine candidate [7]